Autoimmune Hemolytic Anemia Treatment Market Size & Share Analysis - Growth Trends and Forecast (2026 - 2031)

Global Autoimmune Hemolytic Anemia Treatment Market Trends and Insights

Increasing Need for Steroid-Sparing Therapies in Refractory AIHA

Corticosteroids still produce an initial hemoglobin response in many warm autoimmune hemolytic anemia patients, but relapse remains common after tapering, and that keeps the autoimmune hemolytic anemia treatment market tied to repeat treatment cycles.^{[1]Bruno Fattizzo, “Management of Autoimmune Hemolytic Anemia,” Hematology, ASH Education Program, ashpublications.org} Long steroid exposure also raises the burden of diabetes, metabolic complications, and osteoporosis, which lowers quality of life and adds avoidable hospital use even when hemolysis is partly controlled. Rituximab has moved into the preferred second-line position for relapsed or refractory disease, while splenectomy has shifted later because published cohort evidence showed a 12% surgical complication rate. This pattern matters for the autoimmune hemolytic anemia treatment market because every relapse on a prior agent creates a clear switching event once a targeted option is available. The current treatment sequence outlined in the 2025 ASH Education Program also places newer B-cell, plasma-cell, SYK, and FcRn approaches behind rituximab, which supports continued demand across multiple lines of care.

Rising Pipeline Readiness for Complement and FcRn Targeting Therapies

The autoimmune hemolytic anemia treatment market is now moving closer to its first broad wave of labeled targeted therapies, and FcRn blockade is at the center of that shift.^{[2]J.A. Petersen, “Targeting the Neonatal Fc Receptor in Autoimmune Diseases, Pipeline and Progress,” BioDrugs, link.springer.com} FcRn-targeted agents can reduce circulating IgG by as much as 85%, which directly addresses the autoantibodies that drive red blood cell destruction while preserving IgA, IgM, and innate immune function. Nipocalimab is the most advanced FcRn program in warm autoimmune hemolytic anemia and is under FDA Priority Review after showing durable hemoglobin response in the Phase 2/3 ENERGY study. Cold autoimmune hemolytic anemia already has one approved targeted option through sutimlimab, and registry data in more than 70% of treated patients have supported durable real-world effectiveness without new safety signals after a mean treatment duration of more than 2 years. As labeled warm and cold options come into view at the same time, the autoimmune hemolytic anemia treatment market is likely to see stronger physician confidence and better reimbursement support. 

Expanding Orphan-Drug Incentives for Rare Hematology Programs

Orphan-drug incentives continue to support investment in the autoimmune hemolytic anemia treatment market because they improve the economics of development in a rare disease setting. In the United States, orphan designation can provide 7 years of market exclusivity together with other development benefits, and Sanofi’s rilzabrutinib received this status for warm autoimmune hemolytic anemia in April 2025.^{[3]Sanofi, “Rilzabrutinib Granted Orphan Drug Designation in the US for Two Rare Diseases With No Approved Medicines,” Sanofi, sanofi.com} Ouro Medicines also received FDA orphan designation in August 2025 for OM336 after case reports and a broader basket study strategy supported continued development in autoimmune cytopenias. Europe maintained orphan protection for Enjaymo after the product transferred to Recordati, and Japan extended orphan designation to rilzabrutinib in February 2026. With the United States, Europe, and Japan all supporting programs in this space, the autoimmune hemolytic anemia treatment market is attracting both large pharmaceutical companies and specialist biotechs.

Growing Use of Precision Diagnostics to Subtype Warm, Cold, and Mixed AIHA

Accurate subtyping is essential because the autoimmune hemolytic anemia treatment market cannot fully convert incidence into treated demand unless physicians can distinguish warm, cold, mixed, and secondary disease. The direct antiglobulin test remains central to diagnosis, yet false negatives occur in 1% to 10% of cases and leave part of the patient pool in diagnostic uncertainty. Tertiary centers are improving precision through stronger DAT methods, cold antibody titration protocols, and next-generation sequencing panels for red blood cell membrane disorders. This matters commercially because each patient who is correctly identified with cold autoimmune hemolytic anemia can be considered for sutimlimab, while poorly characterized patients often remain on default steroid treatment. ASH-cited international consensus work already supports standardized monospecific DAT as a required part of workup, and wider use of this approach should gradually broaden the treated base for targeted therapies in the autoimmune hemolytic anemia treatment market.

Long Diagnostic Delay Before Confirmed Hematology Referral

Diagnostic delay remains a direct limit on the autoimmune hemolytic anemia treatment market because untreated or misdiagnosed patients do not reach hematology prescribing channels. In low and middle-income countries, pediatric cases have been reported at hemoglobin levels of 3 g/dL to 6 g/dL by the time treatment begins, which reflects long delays between symptom onset and specialist care. Cold autoimmune hemolytic anemia is especially easy to miss because acrocyanosis and cold-triggered circulatory symptoms are often linked to other conditions before hematology referral occurs. Even in higher-income settings, DAT-negative disease can require advanced crossmatch and elution methods that are not widely available in community laboratories. Until referral access, awareness, and diagnostic capability improve more broadly, the autoimmune hemolytic anemia treatment market will continue to face a ceiling on addressable volume.

Small Treatable Patient Pool in Cold Agglutinin Disease and Secondary AIHA

The autoimmune hemolytic anemia treatment market is constrained by the narrow patient base in some subtypes, especially cold agglutinin disease and secondary autoimmune hemolytic anemia. Cold agglutinin disease represents 15% to 20% of all autoimmune hemolytic anemia cases, while secondary disease adds another clinically diverse group shaped by lymphoproliferative disorders, autoimmune disease, and drug exposure. Secondary cases are often excluded from interventional trials, which leaves a gap between the patients seen in practice and the patients covered by formal evidence packages. For cold agglutinin disease, the epidemiology is especially tight at 1 case per 1 million population per year in European settings, which limits the revenue ceiling for dedicated products. Developers are responding with basket studies such as Ouro Medicines’ Phase 1b program across autoimmune cytopenias, but that approach can dilute disease-specific label strength in the autoimmune hemolytic anemia treatment market.

*Our forecasts treat driver/restraint impacts as directional, not additive. The impact forecasts reflect baseline growth, mix effects, and variable interactions.

Segment Analysis

By Type: Warm Subtype Anchors Revenue, Cold AIHA Drives Faster Expansion

Warm autoimmune hemolytic anemia held 68.13% of the autoimmune hemolytic anemia treatment market share in 2025, which matched its position as the most common subtype globally. The autoimmune hemolytic anemia treatment market, therefore, remains centered on warm disease, even though formal targeted approval for this setting is still pending in the United States. That gap means much of the current value in warm disease still comes through corticosteroids and rituximab used off label rather than through premium branded treatment lines. The subtype remains the main target for late-stage programs because it offers the broadest commercial base and the clearest near-term path to label expansion. 

Cold autoimmune hemolytic anemia is projected to grow at an 8.78% CAGR through 2031, supported by sutimlimab’s existing presence and improving real-world evidence. Mixed autoimmune hemolytic anemia remains a smaller revenue pool because it represents only 5% to 8% of cases and often overlaps with complex autoimmune backgrounds such as SLE, where 25% to 42% of mixed cases are associated. Secondary autoimmune hemolytic anemia also remains commercially limited because pivotal studies often exclude these patients, which weakens reimbursement support even when physicians still treat them. Over the longer term, refractory disease may open another layer of value as Juventas Biotechnology’s CAR-T program moved into clinical testing after NMPA IND approval in April 2025.

By Drug Class: Corticosteroids Still Lead, FcRn Inhibitors Set the Pace

Corticosteroids accounted for 57.38% of the autoimmune hemolytic anemia treatment market size in 2025, which reflects entrenched first-line use and low generic acquisition cost rather than durable disease control. That legacy position continues because most patients still begin treatment with steroids even when relapse risk is well understood. Monoclonal antibodies, especially rituximab and biosimilar-linked use, remain important in second-line care and gained fresh support in Japan after the February 2026 approval of rituximab for autoimmune hemolytic anemia. Complement inhibitors hold a defined role in cold disease through sutimlimab, but their growth is naturally capped by the smaller cold agglutinin disease population. 

FcRn inhibitors are the fastest-growing class with a 10.42% CAGR through 2031, and this outlook is tied directly to nipocalimab’s late-stage progress in warm autoimmune hemolytic anemia. The class also benefits from a strong biological rationale because FcRn blockade lowers pathogenic IgG without broadly suppressing other immunoglobulins in the same way. BTK inhibitors are the other key challenger class, and rilzabrutinib posted a 64% overall hemoglobin response rate in 21 primary warm autoimmune hemolytic anemia patients before moving into Phase 3 with Breakthrough Therapy designation. Immunosuppressants, IVIG, and similar supportive options will remain in use, but they are less likely to drive the long-term revenue mix of the autoimmune hemolytic anemia industry once targeted classes become labeled and reimbursed.

By Route of Administration: Intravenous Use Leads Today, Oral Access Gains Ground

Intravenous therapies held 61.16% share of the autoimmune hemolytic anemia treatment market size in 2025 because the leading available and late-stage agents are still mostly infusion based. Sutimlimab, rituximab, and nipocalimab all reinforce a hospital-centered treatment model where diagnosis and treatment initiation are closely linked. This gives intravenous delivery a strong base in current revenue, especially in referral centers that manage severe anemia and transfusion needs. It also explains why hospital and specialty pharmacy systems have remained closely tied to the autoimmune hemolytic anemia treatment market. 

Oral therapies are forecast to grow at a 9.83% CAGR through 2031, driven by BTK inhibitor development and the potential for treatment to move beyond infusion centers. Rilzabrutinib is already supported by an oral specialty distribution structure through its broader regulatory history, which lowers launch friction if warm autoimmune hemolytic anemia approval follows. Subcutaneous delivery remains a smaller but relevant future niche because less burdensome administration could improve persistence in a relapsing disease. As more convenient formats enter care pathways, the autoimmune hemolytic anemia treatment market should gradually shift toward settings that can manage chronic follow-up with less infusion dependence.

By Distribution Channel: Hospital Pharmacy Leads, Online Models Expand Faster

Hospital pharmacy retained 55.12% of the autoimmune hemolytic anemia treatment market share in 2025 because most advanced therapies still flow through inpatient or outpatient infusion settings. This pattern fits a disease area where severe cases often enter care through hospitals and where biologics require close monitoring. It also matches the current delivery profile of sutimlimab, rituximab, and likely early FcRn uptake. As a result, hospital pharmacies remain the main control point for current access in the autoimmune hemolytic anemia treatment market. 

Online pharmacy is projected to expand at 10.98% CAGR through 2031 as rare disease manufacturers continue to rely on specialty hub models for adherence support and co-pay assistance. Retail pharmacy remains secondary because patient complexity, biologic handling requirements, and payer contracting still favor specialty channels. Still, a larger oral pipeline could gradually shift some prescription volume away from hospitals and into specialty and retail networks later in the forecast period. In emerging markets, this transition will remain slower because hospital systems are often still the only structured access route for the autoimmune hemolytic anemia treatment market.

Geography Analysis

North America held 35.63% of the autoimmune hemolytic anemia treatment market share in 2025, which kept it ahead of every other region. The United States remains the core revenue base because it has the deepest concentration of rare blood disorder specialists, the most active regulatory pipeline, and the highest treatment spending per patient. The current U.S. inflection point is the FDA Priority Review for nipocalimab in warm autoimmune hemolytic anemia, which could deliver the first approved targeted therapy for this subtype in late 2026 or early 2027. Commercial readiness is also stronger in this region because specialty pharmacy networks already support adjacent hematology drugs such as fostamatinib, and because Enjaymo has already established physician familiarity with targeted AIHA treatment. Canada and Mexico are expanding rare disease reimbursement, but the autoimmune hemolytic anemia treatment market remains much smaller there on a per-patient basis.

Europe remains the second major region for the autoimmune hemolytic anemia treatment market, anchored by Germany, the United Kingdom, France, Italy, and Spain. The region benefits from a supportive orphan framework, as seen in Enjaymo’s maintained orphan status and the broader openness to orphan programs in autoimmune hemolytic anemia. The United Kingdom still has a key access gap because NICE has not approved an AIHA-specific product, which makes future health technology submissions a major gating step. European clinician awareness is also rising as HUTCHMED presented pivotal sovleplenib Phase 3 data at EHA 2026 in Stockholm, which brought SYK inhibition further into the regional discussion. 

Asia-Pacific is the fastest-growing geography in the autoimmune hemolytic anemia treatment market, with a 9.06% CAGR projected for 2026-2031. Japan strengthened second-line access in February 2026 when rituximab was approved for autoimmune hemolytic anemia, and Sanofi also received orphan designation there for rilzabrutinib in the same month. China is gaining importance through HUTCHMED’s priority-reviewed sovleplenib NDA and Juventas Biotechnology’s CAR-T clinical entry, while the Middle East, Africa, and South America remain smaller but are gradually opening through rare disease policy support and specialist center investment. Diagnostic limits still suppress treated volume in those smaller regions, so growth will depend as much on health system readiness as on product launches.